Key facts
- Notable investors include Neuvation Ventures, Science Center.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Pinco Biotherapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Pinco Biotherapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pinco Biotherapeutics
Developer of DNA plasmid-based therapies designed to enable durable and controllable management of neuropathic pain. The company offers a reversible plasmid drug approach targeting pain-modulating ion channels without complex manufacturing requirements, enabling patients, clinicians, and healthcare systems to address underlying pain mechanisms while improving long-term outcomes and reducing treatment burden.
- Sector
- Healthcare
- HQ
- Princeton, NJ, United States
- Founded
- 2025
- Website
- pincobio.com/
- Ownership
- Privately Held (backing)
Pinco Biotherapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pinco Biotherapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pinco Biotherapeutics in its N-PORT filings yet. We sweep new filings monthly.